Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Asthma-III: Symptoms and Complications

Asthma-III: Symptoms and Complications

Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma

Asthma III: Clinical Manifestations

Asthma III: Clinical Manifestations

Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...

Chronic Obstructive Pulmonary Disease II: Emphysema

Chronic Obstructive Pulmonary Disease II: Emphysema

Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.

Asthma I: Introduction

Asthma I: Introduction

Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

An Eight-Century Evolution of Asthma Therapeutics in Western Countries: From Medieval Regimens to Anti-inflammatory Reliever Therapy and Precision Biologics.

Advances in therapy·2026

Same author

The AIM4 Next Step study: Comparing inhaled corticosteroid dose escalation to dupilumab in patients with uncontrolled asthma and type 2 inflammation.

The journal of allergy and clinical immunology. Global·2026

Same author

Improved asthma outcomes for dupilumab plus medium-dose inhaled corticosteroids versus placebo plus high-dose inhaled corticosteroids.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026

Same author

Moving Beyond Responders: A Post Hoc Analysis Identifying Criteria for Chronic Cough Control.

Chest·2026

Same author

Reply to: Is the role of eosinophils in refractory chronic cough truly dismissed? Mepolizumab reduced blood and sputum eosinophils, but not eosinophil-derived neurotoxin.

The European respiratory journal·2026

Same author

Inhaled anti-thymic stromal lymphopoietin antibody fragment, ecleralimab, in severe asthma: A placebo-controlled, multicenter, double-blind, randomized, phase 2b clinical trial.

American journal of respiratory and critical care medicine·2026

Search research articles

Related Experiment Video

Updated: Jun 28, 2026

Alternative Therapy for Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Moving Cupping Along Meridians

Alternative Therapy for Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Moving Cupping Along Meridians

Published on: September 27, 2024

Severe exacerbations and decline in lung function in asthma.

Paul M O'Byrne¹, Søren Pedersen, Carl Johan Lamm

¹Department of Medicine, McMaster University Medical Center, Ontario, Canada. obyrnep@mcmaster.ca

American Journal of Respiratory and Critical Care Medicine

|November 8, 2008

Summary

This summary is machine-generated.

Severe asthma exacerbations significantly worsen lung function decline. Early treatment with inhaled budesonide (a corticosteroid) can help attenuate this decline, preserving lung function in asthma patients.

Related Experiment Videos

Last Updated: Jun 28, 2026

Alternative Therapy for Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Moving Cupping Along Meridians

Alternative Therapy for Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Moving Cupping Along Meridians

Published on: September 27, 2024

Area of Science:

Pulmonology
Respiratory Medicine
Clinical Trials

Background:

Asthma exacerbations are linked to lung function decline.
The impact of inhaled corticosteroids on this decline requires evaluation.

Purpose of the Study:

To assess the association between severe asthma exacerbations and persistent lung function decline.
To investigate the effect of budesonide on exacerbation-related lung function decline.

Main Methods:

A 3-year randomized, double-blind study (START) involving 7,165 asthma patients.
Investigated early intervention with low-dose inhaled budesonide versus placebo.
Monitored severe asthma events and lung function (FEV1) changes.

Main Results:

Severe exacerbations were linked to a significant decline in FEV1 % predicted in the placebo group (-6.44% vs -2.43%).
This association was significant in children and adults, but not adolescents.
Budesonide treatment showed a trend towards attenuating this decline (-2.48% vs -1.72%), with a statistically significant difference observed.

Conclusions:

Severe asthma exacerbations are associated with accelerated lung function decline.
Early treatment with low-dose inhaled corticosteroids, like budesonide, can mitigate this decline.